Immunomedics Announces Positive Results from Phase 3 ASCENT Study of TRODELVY™ in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer (mTNBC)
06 juil. 2020 07h55 HE
|
Immunomedics
Trodelvy significantly improved progression-free survival (PFS) and overall survival (OS) in previously-treated brain metastasis negative patients with advanced mTNBC The safety profile of Trodelvy...
Immunomedics to Host Conference Call and Webcast on July 6, 2020 to Provide Clinical Update
02 juil. 2020 16h05 HE
|
Immunomedics
MORRIS PLAINS, N.J., July 02, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics to Participate in Upcoming Healthcare Conferences
28 mai 2020 08h00 HE
|
Immunomedics
MORRIS PLAINS, N.J., May 28, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Announces Leadership Change and Provides Business Update Amid COVID-19
27 mai 2020 16h00 HE
|
Immunomedics
MORRIS PLAINS, N.J., May 27, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics to Present New Trodelvy™ Data In Non-Breast Cancer Indications at the 2020 ASCO Virtual Meeting
13 mai 2020 17h01 HE
|
Immunomedics
MORRIS PLAINS, N.J., May 13, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics to Participate in BofA Securities 2020 Health Care Conference
07 mai 2020 08h00 HE
|
Immunomedics
MORRIS PLAINS, N.J., May 07, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Reports First Quarter 2020 Results and Provides Corporate Update
06 mai 2020 16h00 HE
|
Immunomedics
Trodelvy™ received accelerated approval from FDA for third-line metastatic triple-negative breast cancer First patient treated with Trodelvy following successful commercial launch ASCENT study...
Immunomedics Announces Commercial Availability of TRODELVY™ in the United States
04 mai 2020 08h00 HE
|
Immunomedics
MORRIS PLAINS, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Announces Closing Of Public Offering Of Common Stock
01 mai 2020 16h05 HE
|
Immunomedics
MORRIS PLAINS, N.J., May 01, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics to Report First Quarter 2020 Results and Host Conference Call and Webcast On May 6, 2020
30 avr. 2020 08h00 HE
|
Immunomedics
MORRIS PLAINS, N.J., April 30, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...